<code id='20B65E031C'></code><style id='20B65E031C'></style>
    • <acronym id='20B65E031C'></acronym>
      <center id='20B65E031C'><center id='20B65E031C'><tfoot id='20B65E031C'></tfoot></center><abbr id='20B65E031C'><dir id='20B65E031C'><tfoot id='20B65E031C'></tfoot><noframes id='20B65E031C'>

    • <optgroup id='20B65E031C'><strike id='20B65E031C'><sup id='20B65E031C'></sup></strike><code id='20B65E031C'></code></optgroup>
        1. <b id='20B65E031C'><label id='20B65E031C'><select id='20B65E031C'><dt id='20B65E031C'><span id='20B65E031C'></span></dt></select></label></b><u id='20B65E031C'></u>
          <i id='20B65E031C'><strike id='20B65E031C'><tt id='20B65E031C'><pre id='20B65E031C'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:4
          glum Benjamin — health insurance coverage from STAT
          Adobe

          Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

          Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.

          advertisement

          They’re planning on taking a different tack with biotech venture capital. For starters, Scion plans to work on a significantly longer timeframe. Most firms in existence today write checks, help investments grow, and find a way to recoup their money in a 10-year timeframe. Scion is doubling that, setting a 20-year plan for its first fund.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

          CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc

          read more
          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more

          Why age limits for politicians are a terrible idea

          AdobeArecentpollfromYouGov/CBSNewsshowedthat77%ofrespondentssaidthatthereshouldbeamaximumagelimitfor